Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“TCHP. Four letters that have long represented a highly active – yet tough – standard regimen for most patients with stage II-III HER2+ eBC.
For many patients , however, a shorter, carbo-free regimen may be enough.
Thanks to Medscape for highlighting my editorial.”
Triple-Negative Breast Cancer in 2026: A Step-by-Step Clinical Approach From Diagnosis to Treatment
